Collegium Pharma (COLL)

$30.07 +0.21 (0.70%)
Market Cap 966.21M
Revenue (ttm) 631.45M
Net Income (ttm) 69.19M
EPS (ttm) N/A
PE Ratio 5.18
Forward PE 4.88
Profit Margin 10.96%
Debt to Equity Ratio 2.56
Volume 445,400
Avg Vol 277,960
Day's Range N/A - N/A
Shares Out 32.13M
Stochastic %K 25%
Beta 0.68
Analysts Strong Sell
Price Target $44.20

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-dete...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 781 713 3699
Address:
100 Technology Center Drive, Suite 300, Stoughton, United States
Stefan100
Stefan100 Jul. 8 at 3:31 PM
$COLL my research below. Pretty timely as the company is launching another buyback program of $150MM or 15% of market cap https://seekingalpha.com/article/4765962-collegium-pharmaceuticals-shareholders-might-be-in-for-a-pain-free-2025
2 · Reply
Itinerant
Itinerant Jul. 7 at 3:27 PM
$COLL I am impressed with the company's share buyback. They are not wrong. The stock is meaningfully under valued and the analysts' target of $41 is appropriate. I do worry about the legal issues, but the discount rate at $41 is 19%, which is rather substantial anyway.
0 · Reply
ISHARETRADEALERTS
ISHARETRADEALERTS Jul. 7 at 12:00 PM
$COLL - Collegium Announces $150 Million Share Repurchase Program
0 · Reply
Itinerant
Itinerant Jul. 6 at 7:54 PM
$COLL I did a cursory analysis of this company, and while it looks somewhat cheap, I suspect that the market is concerned about the lawsuits. I appreciate that the company is buying in the stock, but the lawsuits are a risky overhang. I guess that is holding the stock down. What do you think?
1 · Reply
jewell69
jewell69 Jun. 6 at 4:34 PM
$COLL got opium ? (a spoof on tv ads, got milk) took profits, but all $IBB $XBI is (APPARENTLY) up today 6/6/25 tryin 2 sell $FRSH 15.72 now b a .63 x .64 12:31 pm EDT
0 · Reply
jewell69
jewell69 Jun. 3 at 5:47 PM
$COLL TRYIN 2 ChASE/ BUY 29.27 LAST TIME WE TOOK PROFITS WAS B4 NICE EARNIN ON 5/8/25 STOCK IS UP SINCE 5/8, BUT 10 DAY gRAPh IS DOWN 2 EYE LAShES Symbol description COLLEGIUM PHARMACEUTICAL INC COM Type Cash Shares -222.000 Price $27.14 Amount $6,023.80 Fees $0.17 Settlement date Apr-29-2025
0 · Reply
jewell69
jewell69 May. 15 at 12:39 AM
$COLL PAIN MEDICINE, seriously. I like 2 joke got opium ? reminds me of Sean Penn / Madonna movie 1986 Shanghai Surprise - takes place in occupied China $MCHI (occupied by $EWJ Japan in 1936) movie starts w/ just SOME of China occupied; but another huge swath of land is imminently being taken over. Opium kingpin tries to move 1100 pounds of opium to safer, quieter remaining $MCHI land. But, Madonna wants all of it.
0 · Reply
jewell69
jewell69 May. 15 at 12:32 AM
$COLL 5/14 CLOSE 29.07 -2.45% TODAY !! 05/13/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 60 $29.779 $0.01 $1,786.73 04/01/2025 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 60 $29.55 -$1,773.00 01/07/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $29.12 $0.19 $5,823.81 01/06/2025 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $28.62 -$5,724.00
0 · Reply
jewell69
jewell69 May. 10 at 8:18 PM
$COLL after close on 5/8 Reports Q1 (Mar) earnings of $1.49 per share, excluding non-recurring items, $0.06 better than the FactSet Consensus of $1.43; revenues rose 22.7% year/year to $177.76 mln vs the $171.95 mln FactSet Consensus. Co reaffirms guidance for FY25, sees FY25 revs of $735-$750 mln vs. $741.47 mln FactSet Consensus 5/9 up 5.94% to 28.89 too bad I paid 29.55 on 4/1 (b4 all _ell broke loose on 4/7 or 4/9 = bottom of market, remember )
0 · Reply
JarvisFlow
JarvisFlow May. 9 at 2:34 PM
Piper Sandler has updated their rating for Collegium Pharmaceutical ( $COLL ) to Neutral with a price target of 37.
0 · Reply
Latest News on COLL
Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Jul 24, 2025, 8:00 AM EDT - 9 days ago

Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025

Collegium Announces $150 Million Share Repurchase Program

Jul 7, 2025, 8:00 AM EDT - 26 days ago

Collegium Announces $150 Million Share Repurchase Program

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

Jun 30, 2025, 2:53 PM EDT - 4 weeks ago

Collegium Pharmaceutical: Stock Deserves A "Buy" Call On Undervaluation Of ADHD Drug

Collegium to Participate in Upcoming Investor Conferences

May 19, 2025, 4:01 PM EDT - 2 months ago

Collegium to Participate in Upcoming Investor Conferences

Collegium Announces $25 Million Accelerated Share Repurchase Program

May 12, 2025, 8:05 AM EDT - 2 months ago

Collegium Announces $25 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

May 9, 2025, 2:04 AM EDT - 3 months ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2025 Earnings Call Transcript

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

May 8, 2025, 4:01 PM EDT - 3 months ago

Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 24, 2025, 8:00 AM EDT - 3 months ago

Collegium to Report First Quarter 2025 Financial Results on May 8, 2025

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 4 months ago

Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Mar 27, 2025, 8:00 AM EDT - 4 months ago

Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Mar 17, 2025, 7:00 AM EDT - 4 months ago

Collegium Announces Updates to its Board of Directors and Executive Leadership Team

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Mar 10, 2025, 6:57 PM EDT - 5 months ago

Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health Care

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Mar 9, 2025, 4:07 AM EDT - 5 months ago

Collegium Pharmaceutical's Shareholders Might Be In For A Pain-Free 2025

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 9:03 PM EST - 5 months ago

Collegium Pharmaceutical, Inc. (COLL) Q4 2024 Earnings Call Transcript

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Feb 27, 2025, 4:01 PM EST - 5 months ago

Collegium Reports Record Fourth Quarter and Full-Year 2024 Financial Results

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Feb 13, 2025, 8:00 AM EST - 6 months ago

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

Collegium Provides 2025 Financial Guidance and Business Update

Jan 8, 2025, 8:00 AM EST - 7 months ago

Collegium Provides 2025 Financial Guidance and Business Update

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Nov 26, 2024, 8:00 AM EST - 8 months ago

Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD Expansion

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Nov 14, 2024, 4:30 PM EST - 9 months ago

Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Nov 8, 2024, 12:30 AM EST - 9 months ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2024 Earnings Call Transcript

Collegium Reports Record Third Quarter 2024 Financial Results

Nov 7, 2024, 4:02 PM EST - 9 months ago

Collegium Reports Record Third Quarter 2024 Financial Results

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 9:30 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2024 Earnings Call Transcript

Collegium Reports Second Quarter 2024 Financial Results

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Collegium Reports Second Quarter 2024 Financial Results

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

Jul 29, 2024, 6:00 AM EDT - 1 year ago

Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology

Collegium to Participate in Jefferies Global Healthcare Conference

May 29, 2024, 8:00 AM EDT - 1 year ago

Collegium to Participate in Jefferies Global Healthcare Conference

Collegium Announces $35 Million Accelerated Share Repurchase Program

May 13, 2024, 8:00 AM EDT - 1 year ago

Collegium Announces $35 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

May 9, 2024, 7:32 PM EDT - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q1 2024 Earnings Call Transcript

Collegium Reports First Quarter 2024 Financial Results

May 9, 2024, 4:02 PM EDT - 1 year ago

Collegium Reports First Quarter 2024 Financial Results

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Apr 25, 2024, 8:00 AM EDT - 1 year ago

Collegium to Report First Quarter 2024 Financial Results on May 9, 2024

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026

Top 10 Small-Cap Stocks (SA Quant)

Mar 12, 2024, 5:00 AM EDT - 1 year ago

Top 10 Small-Cap Stocks (SA Quant)

ANIP APOG BASE BLBD GCT PLMR RAMP

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 9:52 PM EST - 1 year ago

Collegium Pharmaceutical's (COLL) Q4 2023 Earnings Call Transcript

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Feb 22, 2024, 4:09 PM EST - 1 year ago

Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Feb 8, 2024, 8:00 AM EST - 1 year ago

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

Nov 27, 2023, 8:00 AM EST - 1 year ago

Appeals Court Upholds PTAB's Finding of Invalidity of Purdue's 961 Patent

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 10:15 PM EST - 1 year ago

Collegium Pharmaceutical, Inc. (COLL) Q3 2023 Earnings Call Transcript

Collegium Reports Third Quarter 2023 Financial Results

Nov 7, 2023, 4:01 PM EST - 1 year ago

Collegium Reports Third Quarter 2023 Financial Results

Collegium Pharmaceutical: Delivering On Promises

Oct 24, 2023, 2:59 PM EDT - 1 year ago

Collegium Pharmaceutical: Delivering On Promises

Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023

Oct 24, 2023, 8:00 AM EDT - 1 year ago

Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

Aug 28, 2023, 8:00 AM EDT - 2 years ago

Collegium Announces 10 Poster Presentations at PAINWeek Conference 2023

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

Aug 24, 2023, 8:00 AM EDT - 2 years ago

Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026

Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates

Aug 12, 2023, 5:25 AM EDT - 2 years ago

Collegium Pharmaceutical: Pipeline Continues As Share Buyback Initiates

With 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A Buy

Aug 11, 2023, 11:20 AM EDT - 2 years ago

With 30% Returns On Capital Deployed At 4.4x Earnings, Collegium Is A Buy

Collegium Announces $50 Million Accelerated Share Repurchase Program

Aug 7, 2023, 7:30 AM EDT - 2 years ago

Collegium Announces $50 Million Accelerated Share Repurchase Program

Collegium Pharmaceutical, Inc. (COLL) Q2 2023 Earnings Call Transcript

Aug 4, 2023, 4:50 PM EDT - 2 years ago

Collegium Pharmaceutical, Inc. (COLL) Q2 2023 Earnings Call Transcript

Collegium Reports Record 1H'23 Net Revenue of $280.3 Million, Up 35% Year-over-Year

Aug 3, 2023, 4:01 PM EDT - 2 years ago

Collegium Reports Record 1H'23 Net Revenue of $280.3 Million, Up 35% Year-over-Year

Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023

Jul 20, 2023, 8:00 AM EDT - 2 years ago

Collegium to Report Second Quarter 2023 Financial Results on August 3, 2023

Collegium to Participate in Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 2 years ago

Collegium to Participate in Jefferies Healthcare Conference

Collegium: Turning More Constructive, Especially At 4.4x Earnings

May 25, 2023, 8:14 AM EDT - 2 years ago

Collegium: Turning More Constructive, Especially At 4.4x Earnings

Stefan100
Stefan100 Jul. 8 at 3:31 PM
$COLL my research below. Pretty timely as the company is launching another buyback program of $150MM or 15% of market cap https://seekingalpha.com/article/4765962-collegium-pharmaceuticals-shareholders-might-be-in-for-a-pain-free-2025
2 · Reply
Itinerant
Itinerant Jul. 7 at 3:27 PM
$COLL I am impressed with the company's share buyback. They are not wrong. The stock is meaningfully under valued and the analysts' target of $41 is appropriate. I do worry about the legal issues, but the discount rate at $41 is 19%, which is rather substantial anyway.
0 · Reply
ISHARETRADEALERTS
ISHARETRADEALERTS Jul. 7 at 12:00 PM
$COLL - Collegium Announces $150 Million Share Repurchase Program
0 · Reply
Itinerant
Itinerant Jul. 6 at 7:54 PM
$COLL I did a cursory analysis of this company, and while it looks somewhat cheap, I suspect that the market is concerned about the lawsuits. I appreciate that the company is buying in the stock, but the lawsuits are a risky overhang. I guess that is holding the stock down. What do you think?
1 · Reply
jewell69
jewell69 Jun. 6 at 4:34 PM
$COLL got opium ? (a spoof on tv ads, got milk) took profits, but all $IBB $XBI is (APPARENTLY) up today 6/6/25 tryin 2 sell $FRSH 15.72 now b a .63 x .64 12:31 pm EDT
0 · Reply
jewell69
jewell69 Jun. 3 at 5:47 PM
$COLL TRYIN 2 ChASE/ BUY 29.27 LAST TIME WE TOOK PROFITS WAS B4 NICE EARNIN ON 5/8/25 STOCK IS UP SINCE 5/8, BUT 10 DAY gRAPh IS DOWN 2 EYE LAShES Symbol description COLLEGIUM PHARMACEUTICAL INC COM Type Cash Shares -222.000 Price $27.14 Amount $6,023.80 Fees $0.17 Settlement date Apr-29-2025
0 · Reply
jewell69
jewell69 May. 15 at 12:39 AM
$COLL PAIN MEDICINE, seriously. I like 2 joke got opium ? reminds me of Sean Penn / Madonna movie 1986 Shanghai Surprise - takes place in occupied China $MCHI (occupied by $EWJ Japan in 1936) movie starts w/ just SOME of China occupied; but another huge swath of land is imminently being taken over. Opium kingpin tries to move 1100 pounds of opium to safer, quieter remaining $MCHI land. But, Madonna wants all of it.
0 · Reply
jewell69
jewell69 May. 15 at 12:32 AM
$COLL 5/14 CLOSE 29.07 -2.45% TODAY !! 05/13/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 60 $29.779 $0.01 $1,786.73 04/01/2025 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 60 $29.55 -$1,773.00 01/07/2025 Sell Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $29.12 $0.19 $5,823.81 01/06/2025 Buy Trade Details COLL COLLEGIUM PHARMACEUTICAL 200 $28.62 -$5,724.00
0 · Reply
jewell69
jewell69 May. 10 at 8:18 PM
$COLL after close on 5/8 Reports Q1 (Mar) earnings of $1.49 per share, excluding non-recurring items, $0.06 better than the FactSet Consensus of $1.43; revenues rose 22.7% year/year to $177.76 mln vs the $171.95 mln FactSet Consensus. Co reaffirms guidance for FY25, sees FY25 revs of $735-$750 mln vs. $741.47 mln FactSet Consensus 5/9 up 5.94% to 28.89 too bad I paid 29.55 on 4/1 (b4 all _ell broke loose on 4/7 or 4/9 = bottom of market, remember )
0 · Reply
JarvisFlow
JarvisFlow May. 9 at 2:34 PM
Piper Sandler has updated their rating for Collegium Pharmaceutical ( $COLL ) to Neutral with a price target of 37.
0 · Reply
Estimize
Estimize May. 8 at 3:13 PM
Wall St is expecting 1.61 EPS for $COLL Q2 [Reporting 07/31 AMC] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co
0 · Reply
Estimize
Estimize May. 6 at 12:24 PM
Wall St is expecting 1.43 EPS for $COLL Q1 [Reporting 05/08 AMC] http://www.estimize.com/intro/coll?chart=historical&metric_name=eps&utm_co
0 · Reply
jewell69
jewell69 Apr. 28 at 2:42 PM
$COLL sold just now 4/28 11:39 am EDT Type Cash Shares -222.000 Price $27.14 Amount $6,023.80 Fees $0.17 Settlement date Apr-29-2025 BOT 4/23 Type Cash Shares +222.000 Price $26.23 Amount -$5,823.06 Settlement date Apr-24-2025
0 · Reply
Stockpsych11
Stockpsych11 Apr. 27 at 7:41 PM
$COLL like this pick long term.
0 · Reply
KissMyAngus02
KissMyAngus02 Apr. 10 at 6:23 PM
$COLL anyone know why this has been so crushed? it's trading at a 13 P/E.
1 · Reply
JarvisFlow
JarvisFlow Apr. 9 at 1:00 PM
Needham has adjusted their stance on Collegium Pharmaceutical ( $COLL ), setting the rating to Buy with a target price of 46.
0 · Reply
JarvisFlow
JarvisFlow Mar. 24 at 12:30 PM
HC Wainwright & Co. updates rating for Collegium Pharmaceutical ( $COLL ) to Buy, target set at 50.
1 · Reply
dachshund36
dachshund36 Mar. 23 at 5:55 PM
$COLL Does anyone here have experience with Collegium's drugs? Especially wondering about sentiment on Journay. If you needed an ADHD medication for yourself or your family, would you pick this one?
1 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 22 at 12:59 AM
$COLL Digging COLL's strategic moves in pain management and neuropsychiatry. Jornay PM looks promising. Adding to watchlist for potential entry point. insightful article: https://beyondspx.com/article/collegium-pharmaceutical-inc-coll-a-diversified-biopharmaceutical-leader-navigating-growth-and-innovation
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Mar. 11 at 10:03 AM
WATCHLIST MAR 11 2025 $ASML ASML And imec Sign Five-Year Strategic Partnership To Advance Semiconductor R&D And Drive Sustainable Innovation Across Europe $COLL Reported Earlier, Collegium Highlights ADHD Therapy Advances With Jornay PM Posters At 2025 NAPNAP Pediatric Conference $AMD AMD Launches 5th Gen AMD EPYC Embedded Processors For Networking, Storage, And Industrial Edge Markets $TER Teradyne Division Mobile Industrial Robots Launches MiR VDA 5050 Adapter To Support Interoperability For Warehouses, Distribution Centers And Manufacturing Facilities $BTC Bitcoin, Ethereum, Dogecoin Sink Deeper As Recession Worries Overshadow Crypto Market: Arthur Hayes Has This Advice For Risk-Averse Traders
0 · Reply
Stefan100
Stefan100 Mar. 10 at 11:46 AM
$COLL enjoy my research https://seekingalpha.com/article/4765962-collegium-pharmaceuticals-shareholders-might-be-in-for-a-pain-free-2025
1 · Reply
isonize
isonize Mar. 7 at 12:48 AM
$COLL cheap stock !
0 · Reply